Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AUTL vs EVMN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EVMN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–3 Matrix Metrics)

EVMN Overall Winner 6-Pillar Tally: AUTL 2 – 3 EVMN (1 Tie) Matrix Metrics: AUTL 3 – 4 EVMN

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Autolus Therapeutics plc American Depositary Share (AUTL) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). AUTL carries a Unified Composite Score of 40.4/100 (SELL) at $1.14 (N/M Forward P/E, -159.3% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AUTL currently prints a higher short-term Unified Composite Score (40.4/100 SELL vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -159.3% operating margin) and revenue trajectory (+0.0% vs. +94.6% YoY).
  • Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both AUTL (40.4/100 SELL) and EVMN (30.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: AUTL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.2); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AUTL vs EVMN
AUTL NASDAQ
Autolus Therapeutics plc American Depositary Share
Biological Products, (No Disgnostic Substances)
$1.14
-2.56% 1D
Market Cap $311.4M
TTM Revenue $137M
Forward P/E N/M
Beta / 30D Vol 1.66β · 55% Vol
Unified Composite Score
40.4 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.5%), weak momentum, RSI 25
RSI-14: 25.2 · SMA20: $1.42 · SMA50: $1.68
EVMN US Equity Head-to-Head Winner
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47

6-Pillar Scorecard Institutional Category Breakdown (AUTL 2 – 3 EVMN)

Columns: Metric · AUTL · EVMN
1. Valuation Multiples AUTL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 2.3x N/M
2. Growth & Scale AUTL
Revenue Growth (YoY) +94.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $137M N/A
Market Cap $311.4M $315.5M
3. Profitability & Quality EVMN
Gross Margin -45.0% N/A
Operating Margin -159.3% 0.0%
Net Profit Margin -186.4% 0.0%
Return on Equity (ROE) -174.9% -69.5%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$208M EBITDA -$75M
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.10 Book/Sh · -174.9% ROE $52M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 90.0% (<1st %ile) 209.0% (53rd %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AUTL (3) vs EVMN (4)
Institutional Metric AUTL EVMN Criterion Row Edge
Market Capitalization
Scale
$311.4M $315.5M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+94.6% +0.0% Higher Growth AUTL
Operating Margin (TTM)
Profitability
-159.3% 0.0% Higher Margin EVMN
Net Profit Margin
Profitability
-186.4% 0.0% Higher Margin EVMN
Return on Equity (ROE)
Capital Efficiency
-174.9% -69.5% Higher ROE EVMN
52-Week Range Position
Momentum
5% ($1–$3) 8% ($5–$33) Stronger Trend EVMN
Beta / 30D Volatility
Risk Regime
1.66β · 55% Vol 1.05β · 118% Vol Lower Realized Risk AUTL
Unified Institutional Score
Composite Signal
40.4 / 100 (SELL) 30.0 / 100 (SELL) Higher Composite AUTL
Trailing 12M Revenue (USD)
Operating Scale
$137M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-45.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$208M EBITDA ($0.10 Book/Sh · -174.9% ROE) -$75M ($52M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +66.08 pp
AUTL: -28.75% · EVMN: +37.33%
3M Horizon EVMN +0.15 pp
AUTL: -50.22% · EVMN: -50.07%
6M Horizon AUTL +30.9 pp
AUTL: -36.67% · EVMN: -67.57%
1Y Horizon AUTL +50.09 pp
AUTL: -10.94% · EVMN: -61.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AUTL vs EVMN. Trailing 12-month operating profitability (AUTL -159.3% vs EVMN 0.0%) and valuation multiples (AUTL N/M vs EVMN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AUTL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$137M
Gross Margin-45.0%
Op. Margin-159.3%
ROE / Fwd P/E-174.9% · N/M
EVMN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AUTL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 90.0%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AUTL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AUTL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $311.4M market capitalization and -159.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AUTL vs EVMN Key Questions & Quantitative Answers

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Autolus Therapeutics plc American Depositary Share (AUTL) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). AUTL carries a Unified Composite Score of 40.4/100 (SELL) at $1.14 (N/M Forward P/E, -159.3% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AUTL currently prints a higher short-term Unified Composite Score (40.4/100 SELL vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -159.3% operating margin) and revenue trajectory (+0.0% vs. +94.6% YoY). Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both AUTL (40.4/100 SELL) and EVMN (30.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: AUTL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.2); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AUTL leads the Growth & Scale pillar: AUTL posts +94.6% YoY revenue growth and +0.0% YoY earnings growth on $137M TTM revenue (-45.0% gross margin, -159.3% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AUTL generates $137M in USD-normalized revenue versus N/A for EVMN. In operating R&D and SG&A reinvestment, AUTL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.

AUTL screens cheaper on headline valuation multiples. AUTL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (unreported EBITDA margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AUTL (-174.9% ROE) versus EVMN (-69.5% ROE) capital efficiency.

In options market volatility and institutional positioning, AUTL carries 90.0% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 55% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.